Compare BLD & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLD | BBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 14.4B |
| IPO Year | N/A | 2019 |
| Metric | BLD | BBIO |
|---|---|---|
| Price | $437.19 | $74.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 20 |
| Target Price | ★ $429.38 | $75.75 |
| AVG Volume (30 Days) | 260.8K | ★ 2.0M |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 19.67 | N/A |
| Revenue | ★ $5,236,045,000.00 | $353,780,000.00 |
| Revenue This Year | $2.39 | $128.44 |
| Revenue Next Year | $13.47 | $76.14 |
| P/E Ratio | $22.16 | ★ N/A |
| Revenue Growth | N/A | ★ 62.46 |
| 52 Week Low | $266.26 | $25.34 |
| 52 Week High | $461.49 | $75.24 |
| Indicator | BLD | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 68.19 |
| Support Level | $418.75 | $70.35 |
| Resistance Level | $454.91 | $75.10 |
| Average True Range (ATR) | 13.90 | 2.33 |
| MACD | -0.60 | -0.13 |
| Stochastic Oscillator | 40.77 | 98.77 |
TopBuild Corp is an installer and distributor of insulation products. Its operating segments involve the Installation and Specialty Distribution segment. The installation segment provides insulation installation services nationwide through contractor services business. Speciality Distribution segment distributes building and mechanical insulation, insulation accessories and other building product materials for the residential, commercial, and industrial end markets. The majority of revenue is earned from the installation segment. Its main customers are contractors. Other products include gutters, after-paint, garage doors, fireplaces, and fireproofing and stopping. TopBuild operates majorly in the United States.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.